BRIEF-Bristol-Myers' Nivolumab study reaches limit, suspends recruitment - Clinicaltrials.gov
Jan 6 Clinicaltrials.gov
* Bristol-Myers' study of Nivolumab with, without Ipilimumab treating patients with Metastatic Sarcoma that can't be removed suspended recruitment - Clinicaltrials.gov
* Bristol-Myers' Nivolumab study suspended per complete sheet, pre-registration limit reached - Clinicaltrials.gov Source (bit.ly/2iQj5Gj) Further company coverage:
Loeb's Third Point hedge fund targeting Nestle for strategic changes- Bloomberg
June 25 Nestle SA, is being targeted by activist investor Daniel Loeb's hedge fund Third Point LLC, Bloomberg reported, citing people familiar with the matter.